Mitch Raponi
Veridex
L.L.C. a Johnson & Johnson Company
San Diego
California 92121
USA
Name/email consistency: high
- Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Raponi, M., Harousseau, J.L., Lancet, J.E., Löwenberg, B., Stone, R., Zhang, Y., Rackoff, W., Wang, Y., Atkins, D. Clin. Cancer Res. (2007)
- Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Raponi, M., Zhang, Y., Yu, J., Chen, G., Lee, G., Taylor, J.M., Macdonald, J., Thomas, D., Moskaluk, C., Wang, Y., Beer, D.G. Cancer Res. (2006)
- Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. Raponi, M., Belly, R.T., Karp, J.E., Lancet, J.E., Atkins, D., Wang, Y. BMC. Cancer (2004)